News: Italian narsoplimab study boosts Covid-19 survival

Omeros is assessing narsoplimab in the I-SPY COVID-19 Trial for critically ill Covid-19 patients in Italy. The trial has reported an 80% rate of recovery, survival and discharge in their clinical trial of 10 subjects receiving the treatment under compassionate use.


The trial has taken place in Bergamo, Italy and enrolled subjects who were afflicted by the second covid-19 surge in the country. The treatment was given between October 2020 and April 2021, and was delivered as a twice-weekly intravenous dose. Participants had a median age of 65, with a median of six doses given.


The cohort enrolled patients with comorbidities that might impact survival ratings or overall outcome, such as diabetes, heart diseases, and obesity. Of the cohort, 8-% were in severe acute respiratory distress at the time of admission to the intensive care unit and intubation.


Of the two deaths reported, both had pre-existing illnesses and experienced complications as a result of their conditions. One also only received the treatment 13 days after his initial intubation.


The chairman and CEO of Omeros, Gregory Demopulos stated in an interview with clinical trials arena: “Unlike other drugs for Covid-19, narsoplimab targets the inflammatory endothelial disease – a central driver across variants.”


The treatment comes alongside a shifting global focus toward therapeutics to combat hospitalization and deaths following Covid-19 contraction.


Want to learn more?


In addition to reporting clinical trial news and stories from within the patient community, we operate Citrus, a fully integrated recruitment and retention software. Citrus fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.

Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.


Check out what our customers have to say about us here.

And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.